ADAA’s licensed mental health providers specialize in anxiety, depression, OCD, PTSD, and related disorders. All listed providers, offering both in-person or virtual therapy, are ADAA members who have chosen to be listed.
Learn More
Boost Search Results
Off
Sanjay J. Mathew, M.D. is the Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research and Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center (MEDVAMC) in Houston, Texas. He graduated from Dartmouth College and Baylor College of Medicine, and trained in psychiatry at Columbia University and the New York State Psychiatric Institute, where he also completed a NIH-funded research fellowship in affective and anxiety disorders. Dr. Mathew began his faculty career at the Icahn School of Medicine at Mount Sinai where he co-founded and directed the Mood & Anxiety Disorders Program. In 2010, Dr. Mathew was recruited back to his hometown of Houston to direct Baylor’s Mood & Anxiety Disorders Program. His research program focuses on developing novel therapies for patients with treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting glutamate-modulating agents.
Dr. Mathew’s research program has been funded by NIMH, Department of Veterans Affairs, Patient-Centered Outcomes Research Institute (PCORI), and industry in the areas of experimental therapeutics and pathophysiology of treatment-resistant depression, suicide, and PTSD. He has authored or co-authored over 130 manuscripts and book chapters, and serves on the editorial board of several journals. In addition to his long involvement with ADAA including serving as Chair of the Program Committee (2017-2018), Dr. Mathew is a member of the American College of Neuropsychopharmacology, and board member of the American Society of Clinical Psychopharmacology. An active clinician and teacher, Dr. Mathew has been selected by his peers as a “Best Doctor” every year since 2011, and has received awards for his teaching of psychopharmacology.
Dr. Mathew has been an ADAA member since 2000 and is currently ADAA's Chief Medical Officer and the ADAA Board Secretary.
Why I am an ADAA Member
ADAA is a unique organization which blends clinicians with researchers, and unlike many professional organizations, includes a wide range of mental health professionals in its membership. As a psychiatrist and researcher, I especially appreciate the opportunity to interact in meaningful ways with colleagues across the country whose primary identity is clinical. I also appreciate ADAA's demographic inclusiveness and mission to promote the next generation of clinicians, teachers, and researchers in our field.
What do I value most about the ADAA mission and how does my work fit in?
My research primarily is focused on developing new drug treatments for depression and PTSD, and understanding biomarkers associated with these illnesses and treatments. ADAA as an organization recognizes the inseparability of anxiety and depression, and has increasingly encouraged participation for those whose main interests are related to mood disorders. ADAA truly operates year-round and not just at its Annual Conference by providing webinars run by experts in the field.The annual conference also provides an awesome opportunity to learn about cutting-edge research and clinical developments in the field, while meeting new colleagues and old friends.It is certainly one of the highlights of my year!
What is exciting about what his happening in my lab/research?
We are doing studies which run the gamut from large multicenter clinical trials (such as a PCORI funded comparison of IV ketamine and ECT for treatment-resistant depression), to small NIH-funded experimental medicine studies in PTSD and depression which use an experimental drug as a probe of a specific brain circuit or neurophysiological measure. The former type of study can immediately impact clinical practice, which is exciting. The latter type of study will not have an immediate impact on patient care but hopefully will lead to a better understanding of how a specific drug mechanism impacts specific aspects of brain function and behavior. It is gratifying to be involved in both types of projects and keeps our team focused on both short-term and longer-term research questions.
